deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00003875

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

Treatment of Acute Myelogenous Leukemia With Busulfan and Etoposide Followed by Autologous or Syngeneic Stem Cell Rescue and Low-Dose Interleukin 2 (IL-2) Immunotherapy

Sponsor: Fred Hutchinson Cancer Center

Conditions Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia in Remission Childhood Acute Myeloid Leukemia in Remission Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia
Interventions aldesleukin busulfan etoposide peripheral blood stem cell transplantation
Updated 7 times since 2017 Last updated: May 3, 2017 Started: Oct 13, 1998 Primary completion: Jun 11, 2015 Completion: Jun 11, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003875, this PHASE2 trial focuses on Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and Adult Acute Myeloid Leukemia With Del(5q) and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 7 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshotCompleted~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~May 2022 · 16 months · monthly snapshotCompleted~May 2022 – ~Jul 2024 · 26 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jul 2017 [monthly]

    Completed PHASE2

    First recorded

Oct 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations